New 1,3,4-Thiadiazole Derivatives with Anticancer Activity

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Cancer Biology

Background:

• 1,3,4-thiadiazole derivatives are recognized for diverse biological activities.
• Developing novel cytotoxic agents against breast cancer remains a critical research area.
• Understanding mechanisms of action is crucial for drug development.

Purpose of the Study:

• To design and synthesize novel 1,3,4-thiadiazole derivatives.
• To evaluate the cytotoxic and anti-proliferative effects of these compounds on breast cancer cell lines (MCF-7, MDA-MB-231) and normal fibroblasts.
• To investigate the potential mechanism of action of the synthesized compounds.

Main Methods:

• Synthesis of 1,3,4-thiadiazole derivatives with varying substituents at C2 and C5 positions.
• In vitro cytotoxic assays using MCF-7, MDA-MB-231, and fibroblast cell lines.
• Determination of half-maximal inhibitory concentration (IC50) values.
• In silico studies to predict the mode of action.

Main Results:

• The compound 2-(2-trifluorometylophenylamino)-5-(3-methoxyphenyl)-1,3,4-thiadiazole exhibited the strongest anti-proliferative activity against both MCF-7 (IC50 = 49.6 µM) and MDA-MB-231 (IC50 = 53.4 µM) cells.
• All synthesized compounds demonstrated significantly lower cytotoxicity towards normal fibroblasts compared to breast cancer cells.
• In silico analysis suggested a multitarget mechanism, potentially involving Caspase 3, Caspase 8, and BAX protein activation.

Conclusions:

• The synthesized 1,3,4-thiadiazole derivatives possess significant cytotoxic potential against breast cancer cells.
• The lead compound displays selective toxicity towards cancer cells, indicating therapeutic promise.
• The findings suggest that these compounds may exert their effects through modulation of apoptosis-related pathways.